title: [Is ophthalmologic screening essential during alpha interferon treatment?].
authors.forename: E
authors.initials: E
authors.lastname: Emonet-Mercier
authors.forename: J P
authors.initials: JP
authors.lastname: Touraud
authors.forename: P
authors.initials: P
authors.lastname: Tsan
authors.forename: J
authors.initials: J
authors.lastname: Chapard
authors.forename: S
authors.initials: S
authors.lastname: Dalac
authors.forename: D
authors.initials: D
authors.lastname: Lambert
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D012170:Retinal Vein Occlusion / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha